Samsung Medical Center-Lymphoma Cohort Study

NCT00822731 | Completed DMC

• 1 other identifier: 2008-08-068
• Study Type: interventional
• Target: 953
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Conditions

Lymphoma

Keywords

Lymphoma; prognosis; morbidity

Outcome Measures

Primary Outcomes (1)

• all cause mortality

  5 years

Secondary Outcomes (3)

• Treatment response

  after completion of primary therapy

• Rate of occurrence of toxicity

  2 years from the start of the 1st therapy

• Treatment-related morbidity

  within 60 days from the previous therapy

Study Arms (1)

Lymphoma

EXPERIMENTAL

patients diagnosed as lymphoma

Drug: Chemotherapy with or without radiotherapy

Interventions

Chemotherapy with or without radiotherapy DRUG

Treatment regimen will be determined by the sub-type of lymphoma

Also known as: Chemotherapy:CHOP, RCHOP, (R)HyperCVAD

Lymphoma

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who were diagnosed as lymphoma
• Over 15 years old
• Patients who agreed the enrollment of study
• Informed consent for sampling

You may not qualify if:

• Patients who do not want to join the study

Sponsors & Collaborators

• Samsung Medical Center: lead

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Related Publications (4)

• Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020 Feb 13;20(1):120. doi: 10.1186/s12885-020-6612-2.

  PMID: 32054467 DERIVED

• Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH, Kim WS. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica. 2015 Mar;100(3):e106-9. doi: 10.3324/haematol.2014.116087. Epub 2014 Dec 5. No abstract available.

  PMID: 25480498 DERIVED

• Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4.

  PMID: 25475080 DERIVED

• Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ, Kim WS. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study. Ann Hematol. 2012 Nov;91(11):1747-56. doi: 10.1007/s00277-012-1516-0. Epub 2012 Jun 28.

  PMID: 22739576 DERIVED

MeSH Terms

Conditions

Lymphoma

Interventions

Drug Therapy; Radiotherapy

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

• Seok Jin Kim, MD, PhD

  Samsung Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 30, 2008
• First Posted: January 14, 2009
• Study Start: September 1, 2008
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: May 23, 2012

Record last verified: 2012-05

Locations

KR (1)